Literature DB >> 12818251

Cooperative effect of GNB3 825C>T and GPIIIa PI(A) polymorphisms in enhanced platelet aggregation.

Ulrich H Frey1, Nese Aral, Norbert Müller, Winfried Siffert.   

Abstract

INTRODUCTION: Platelet aggregation contributes to various thrombembolic disorders. Environmental factors affect platelet aggregability but only partially explain the interindividual variability in aggregation. While the platelet glycoprotein IIb/IIIa is involved in the pathogenesis of acute coronary syndromes whereas most platelet activating stimuli act via G Protein coupled receptors we investigated whether the 825C>T polymorphism of the gene GNB3 encoding the G protein beta3 subunit together with the platelet glycoprotein (GP) IIIa Pl(A) polymorphism are predictive of platelet aggregability on stimulation with various agonists acting via GPCRs.
MATERIALS AND METHODS: Platelet aggregation was measured by turbidometry in 150 non-smoking individuals aged 18-40 years at a density of 2 x 10(5) platelets/microl with various agonists according to the method of Born. Genotypes of the GNB3 825C>T and glycoprotein IIb/IIIa PI(A) polymorphisms were determined using Pyrosequencing technology and restriction analysis. All functional studies were completed within 3 h. The data were analysed by Student's t-test for paired data.
RESULTS: Low concentrations of agonists resulted in enhanced platelet aggregation in subjects with the GNB3 CC-genotype compared to carriers of a 825T-allele. This effect was further enhanced in carriers of the GPIIIa Pl(A2) allele (2 microM ADP: 42% vs. 19%, p=0.017; 1 microM U-46619: 51% vs. 30%, p=0.03; 5 microM epinephrine: 69% vs. 53%, p=0.025). No significant pattern of aggregation was observed on stratification by GPIIIa genotypes alone.
CONCLUSIONS: Our findings indicate that two genetic markers contribute synergistically to increased platelet aggregation. This will help to identify patients at increased risk for thrombosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818251     DOI: 10.1016/s0049-3848(03)00253-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Molecular cloning and expression of glycoprotein IIIa(T1565C).

Authors:  Lei Ren; Limei Zhang; Yanhong Liu
Journal:  Mol Biol Rep       Date:  2008-09-02       Impact factor: 2.316

Review 2.  Pharmacogenetics of aspirin resistance: a comprehensive systematic review.

Authors:  Timothy Goodman; Albert Ferro; Pankaj Sharma
Journal:  Br J Clin Pharmacol       Date:  2008-04-22       Impact factor: 4.335

3.  Xueshuan Xinmaining Tablet Treats Blood Stasis through Regulating the Expression of F13a1, Car1, and Tbxa2r.

Authors:  Xiaotian Zhang; Chao Zhang; Jingying Sai; Fan Li; Jinping Liu; Yang Li; Fang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-02       Impact factor: 2.629

4.  Interactions among COX-2, GPIIIa and P2Y1 variants are associated with aspirin responsiveness and adverse events in patients with ischemic stroke.

Authors:  Xingyang Yi; Zhao Han; Qiang Zhou; Jing Lin; Chun Wang
Journal:  Ther Adv Neurol Disord       Date:  2016-12-01       Impact factor: 6.570

5.  Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients.

Authors:  Xingyang Yi; Chun Wang; Qiang Zhou; Jing Lin
Journal:  BMC Neurol       Date:  2017-01-09       Impact factor: 2.474

6.  Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis.

Authors:  Jing Wang; Jie Liu; Yaqing Zhou; Fei Wang; Ke Xu; Deyu Kong; Jianling Bai; Jun Chen; Xiaoxuan Gong; Haoyu Meng; Chunjian Li
Journal:  Sci Rep       Date:  2019-09-11       Impact factor: 4.379

7.  Investigating the genetic architecture of disease resilience in pigs by genome-wide association studies of complete blood count traits collected from a natural disease challenge model.

Authors:  Xuechun Bai; Tianfu Yang; Austin M Putz; Zhiquan Wang; Changxi Li; Frédéric Fortin; John C S Harding; Michael K Dyck; Jack C M Dekkers; Catherine J Field; Graham S Plastow
Journal:  BMC Genomics       Date:  2021-07-13       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.